assay · intermediate · partly written
Hepatocyte stability assay
Whole liver cells are incubated with a compound and parent depletion gives intrinsic clearance, with uptake transporters and conjugation enzymes present.
Also called: hepatocyte clearance
How well it predicts: the numbers depend on the dataset more
Human hepatocytes, 101 drugs, well-stirred model: average fold error 2.7, 30.7 percent within 2-fold and 62.4 percent underpredicted; by extraction class (n=55, 28, 18) the fold error was 2.1, 3.2 and 4.8 and the share within 2-fold 34.6, 35.7 and 11.1 percent; only 1 of 18 high-extraction drugs was classified as high. An older database found a bias of about 5-fold for microsomes and 4-fold for hepatocytes, with the parallel-tube model helping only marginally. In a blinded multi-company set of 19 drugs with intravenous data, hepatocyte prediction without binding was within 2-fold for 78 percent, and the best methods reached 78 percent within 2-fold, 94 percent within 3-fold and 100 percent within 10-fold. One company reported about 71 percent of key PK parameters within 2-fold across 116 candidates, self-reported. 1234
Contested
Why it misses more
The authors of the 101-drug study propose cofactor depletion, loss of enzyme activity, permeability limits, the unstirred water layer and errors in protein binding, and call the mechanism undetermined. The high-extraction group contains only 2 drugs within 2-fold, so 11.1 percent is not a stable rate. 1
Reported, not yet replicated
Question answered
How fast intact liver cells remove the compound, including uptake and conjugation, so human hepatic clearance can be estimated. 1
Reported, not yet replicated
Readout physical
Remaining parent at set times, scaled per million cells; the same depletion readout as the microsomal assay. 1
Our inference
Not measured
Anything outside the liver, and the whole-liver behaviour the stirred-tank equation hides; standard assays predict poorly for low-turnover compounds (one vendor poster, overview only). 1
Reported, not yet replicated
Setting
Where in cascade
Still open here
- Cost, throughput and run time with basis and date.
- The low-turnover relay method from a primary source.
Not yet written: Sample prep, Conditions, Throughput class, Throughput, Time per run, Cost, Engineerable variants, Use cases, Before after, Capital, Emerging, ML role, Data availability.
Linked from
Sources
- Bowman CM, Benet LZ. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction. J Pharm Sci (2019). paper; opened 2026-11-17 all records citing this
- Hallifax D, Foster JA, Houston JB. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res (2010). paper; opened 2026-11-17 all records citing this
- Ring BJ, Chien JY, Adkison KK, Jones HM, et al.. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci (2011). paper; opened 2026-11-17 all records citing this
- Davies M, Jones RDO, Grime K, Jansson-Löfmark R, et al.. Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades. Trends Pharmacol Sci (2020). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/assays/hepatocyte-stability-assay.json